Medicus Pharma Ltd.
For the period ended Dec 31, 2025. Filed Mar 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 25, 2026
MDCX$1.89+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
Consolidated Statements of Operations and Comprehensive Loss
| Years Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating expenses: | ||
| General and administrative | $17,920,391 | $7,653,116 |
| Research and development | 7,721,436 | 3,527,786 |
| In-process research and development (IPR&D) - Teverelix | 8,717,475 | - |
| Total operating expenses | 34,359,302 | 11,180,902 |
| Loss from operations | (34,359,302) | (11,180,902) |
| Other income (expense) | ||
| Interest income (expense) | (197,382) | 25,386 |
| Loss on SEPA settlements | (278,854) | - |
| Change in fair value of debentures | (583,823) | - |
| Loss on extinguishment of debentures | (25,000) | - |
| Total other income (expense) | (1,085,059) | 25,386 |
| Net loss for the year | (35,444,361) | (11,155,516) |
| Deemed dividend on warrant inducement | (11,837,298) | - |
| Net loss for the year attributable to common shareholders | (47,281,659) | (11,155,516) |
| Foreign currency translation adjustment | (10,730) | - |
| Comprehensive loss for the year attributable to common shareholders | (47,292,389) | (11,155,516) |
| Net loss attributable to | ||
| Common shareholders of the Company | (47,281,513) | (11,155,516) |
| Non-controlling interests | (146) | - |
| Comprehensive loss attributable to | ||
| Common shareholders of the Company | (47,292,239) | (11,155,516) |
| Non-controlling interests | (150) | - |
| Net loss per share attributable to common shareholders - basic and diluted | $(2.74) | $(1.16) |
| Weighted average number of common shares outstanding - basic and diluted | 17,283,824 | 9,619,184 |
The accompanying notes are an integral part of these consolidated financial statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.